RESTORE: Natural Microbiota Restoration After C-section Birth

Sponsor
Institut National de la Santé Et de la Recherche Médicale, France (Other)
Overall Status
Completed
CT.gov ID
NCT02567071
Collaborator
(none)
33
1
3
35.8
0.9

Study Details

Study Description

Brief Summary

The proportion of cesarean deliveries reached 30% of births in the US in 2008, while in the 1970s, it rarely reached 15%, as recommended by WHO. According to recent reports in some hospitals in China the use of cesarean section increased from 5% in the 1970s to over 60%. The use of C-section continues to grow in every countries of the world despite that current knowledge leads us to think that the vaginal birth, retained through millennia during mammalian evolution, guarantees the implementation of the best suited intestinal microbiota to build immunity and beneficial protective functions under the balanced mutual association between the host and its microbiota. Oral administration of a previously impregnated swab, by vaginal and maternal perineal secretions, following birth by planned C-section, would restore the normal development of the newborn intestinal microbiota mimicking exposure to these secretions during vaginal delivery.

The expected benefit is the establishment of a rich and diverse microbiota in individuals in the intervention group and by extension improving the overall health of these individuals.

Condition or Disease Intervention/Treatment Phase
  • Other: perineal impregnated swab
  • Other: clean swab
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
33 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
Retablissement Du Microbiote Naturel Apres Naissance Par Cesarienne
Actual Study Start Date :
Apr 6, 2016
Actual Primary Completion Date :
Apr 1, 2019
Actual Study Completion Date :
Apr 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Group

75 children born by planned C-section will be exposed to the perineal microbiota of their mothers through perineal impregnated swab.

Other: perineal impregnated swab
After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.

Placebo Comparator: Placebo Group

75 children born by planned C-section will be exposed to clean swab.

Other: clean swab
After planned C-section birth, newborns will suck on clean swab.

No Intervention: Control Group

75 children born vaginally.

Outcome Measures

Primary Outcome Measures

  1. Diversity of the intestinal microbiota [1 year]

    Intestinal microbiota diversity will be evluated through metagenomics.

Secondary Outcome Measures

  1. Health status [1 year]

    Health status of the newborn will be evaluated through questionnaries.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • over the age of legal majority

  • delivery by planned C-section at term or vaginal delivery at term

  • registered at a social security service

Exclusion Criteria:
  • HIV or other STD patients

  • immunocompromised patients

  • known streptococcus B carriers

  • known vaginal or perineal herpes infections

  • chronic disease patients (obesity, diabetes, IBD)

  • IMC before pregnancy > 30 kg/m²

  • antibiotic treatments one month before delivery

  • emergency C-section

  • Premature delivery (<37 amenorrhea weeks)

  • hospitalized for more than one week before delivery

  • known HVC infections

  • for the newborns: every diagnosed anomaly

  • patients who do not understand the research procedures or those that are institutionalized, or those unable to give informed consent

  • patients deprived of ther liberty by legal or administrative decisions

  • patients under an exclusion period from another study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Service de Gynécologie-Obstétrique, Groupe Hospitalier Pitié-Salpêtrière Paris France 75013

Sponsors and Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Investigators

  • Principal Investigator: Jacky Nizard, MD, PhD, APHP

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier:
NCT02567071
Other Study ID Numbers:
  • C14-70
  • 2015-A00586-43
First Posted:
Oct 2, 2015
Last Update Posted:
Aug 26, 2021
Last Verified:
Aug 1, 2021
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France

Study Results

No Results Posted as of Aug 26, 2021